PT-141 (Bremelanotide)

A melanocortin receptor agonist derived from melanotan II. Unlike the rest of this catalog, bremelanotide is an APPROVED MEDICINE: the FDA approved it in June 2019 under the name VYLEESI for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Activates melanocortin receptors MC3R and MC4R in the hypothalamus and limbic regions. It acts centrally, on the neural pathways of desire — not on blood flow, which is what distinguishes it from the PDE5 inhibitor class.

Hypoactive sexual desire disorder in premenopausal women, its approved indication. Use in men has been investigated but has no approved indication.

Lyophilized. Reconstitute with bacteriostatic water per the general reference below.

General reconstitution & storage reference for lyophilized peptides:

1. 1Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water — the preservative meaningfully extends usable shelf life.
2. 2In bacteriostatic water, refrigerate at 2–8°C, typically usable for ~28–30 days. In plain sterile water (no preservative): 7–14 days.
3. 3Lyophilized (unmixed) vials are stable at refrigerated or, for some peptides, frozen temperatures for extended periods prior to reconstitution.
4. 4Avoid repeated freeze-thaw cycles, direct light/UV exposure, and heat — these are the primary drivers of peptide degradation.
5. 5Reconstitute gently: inject the water down the inside wall of the vial and swirl — don't shake, which can denature the peptide structure.

Nausea is the most frequent adverse effect reported in trials, followed by flushing, injection-site reactions and headache. The approved label limits dosing to one dose in 24 hours and no more than eight per month, and the product is dispensed under prescription.

• FDA — Vyleesi (bremelanotide), aprobación 2019
• PubMed — bremelanotide, ensayos RECONNECT